Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dermelix gains EspeRare's DMX101 for ultra-rare disease XLHED

Executive Summary

Dermelix Biotherapeutics and the Swiss non-profit organization EspeRare Foundation are collaborating on the development and commercialization of DMX101 (formerly known as ED1200 and ER004) for the ultra-rare pediatric disease X-linked hypohidrotic ectodermal dysplasia (XLHED), which is caused by a deficiency of ectodysplasin A (EDA), a protein required for the normal formation of structures such as sweat and respiratory glands, skin, hair, and teeth.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies